Loading…

Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition

Aims The present study was designed to test the hypothesis that NADPH oxidase inhibition with apocynin would lower blood pressure and improve endothelial function in spontaneously hypertensive rats (SHRs). Although apocyin effectively dilated arterial segments in vitro, it failed to lower blood pres...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular research 2008-11, Vol.80 (2), p.271-279
Main Authors: Schlüter, Torsten, Steinbach, Antje C., Steffen, Anja, Rettig, Rainer, Grisk, Olaf
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03
cites cdi_FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03
container_end_page 279
container_issue 2
container_start_page 271
container_title Cardiovascular research
container_volume 80
creator Schlüter, Torsten
Steinbach, Antje C.
Steffen, Anja
Rettig, Rainer
Grisk, Olaf
description Aims The present study was designed to test the hypothesis that NADPH oxidase inhibition with apocynin would lower blood pressure and improve endothelial function in spontaneously hypertensive rats (SHRs). Although apocyin effectively dilated arterial segments in vitro, it failed to lower blood pressure or improve endothelial function. Further experiments were performed in normotensive rats and in NADPH oxidase subunit knock-out mice to test if apocynin-induced vasodilation depends on NADPH oxidase inhibition at all. Methods and results SHRs were treated with apocynin orally or i.v. Arterial pressure was recorded directly. Rat and mouse arterial function was investigated in vitro by small vessel wire myography. NADPH oxidase activity was measured in human granulocytes and in rat vascular preparations. Rho kinase activity was determined by Western blot analysis. Apocynin did not reduce arterial pressure acutely in SHR when given at 50, 100, or 150 mg kg−1 day−1 orally over 1-week intervals or when given i.v. Apocynin potently inhibited granulocyte NADPH oxidase but not vascular NADPH-oxidase-dependent oxygen radical formation unless exogenous peroxidase was added to vascular preparations. Apocynin dilated rat intrarenal and coronary arteries independently of pharmacological interventions that reduce vascular superoxide radical abundance and actions. Aortic rings from p47phox−/− mice were more sensitive to apocynin-induced dilation than wild-type aortic rings. Rho kinase inhibition reduced or prevented the inhibitory effect of apocynin on agonist-induced vasoconstriction and apocynin inhibited the phosphorylation of Rho kinase substrates. Conclusion Apocynin per se does not inhibit vascular NADPH-oxidase-dependent superoxide formation. Its in vitro vasodilator actions are not due to NADPH oxidase inhibition but may be explained at least in part by inhibition of Rho kinase activity. The discrepancy between apocynin-induced vasodilation in vitro and the failure of apocynin to lower arterial pressure in SHR suggests opposing effects on arterial pressure-regulating systems in vivo. Its use as a pharmacological tool to investigate vascular NADPH oxidase should be discontinued.
doi_str_mv 10.1093/cvr/cvn185
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69668468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cvr/cvn185</oup_id><sourcerecordid>69668468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03</originalsourceid><addsrcrecordid>eNp90EFLIzEUB_AginbVix9A5qIHYfSlmSSTY6m6XSy6rgoiSMhkEoxOkzqZKfrtN7stihcP4ZG8Hy-8P0J7GI4xCHKiF206Hpd0DQ0wpzQnw4KuowEAlDkjjGyhHzE-pyulvNhEW4kKBlQM0ONoHvS7dz53vu61qbOFiqF2jepc8Jnzi9AsTMz-PIXsxXkVTXp7cpX73676LvOhyy5Hp78nWXhz9VewgzasaqLZXdVtdHd-djue5NOrn7_Go2muCyy63CpWMoIJB1sQY2sKxhLFSEW4AVsBFoITMMCJsFDBUBBWFaqmKq3DsQayjQ6Xc-dteO1N7OTMRW2aRnkT-iiZYKwsWJng0RLqNsTYGivnrZup9l1ikP_ClClMuQwz4f3V1L6amfqTrtJL4GAFVNSqsa3y2sUPNwTOaVrq04V-_v2H-dK52Jm3D6naF8k44VRO7h_kLdzT6c21kBfkL8LMmgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69668468</pqid></control><display><type>article</type><title>Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition</title><source>Oxford Journals Online</source><creator>Schlüter, Torsten ; Steinbach, Antje C. ; Steffen, Anja ; Rettig, Rainer ; Grisk, Olaf</creator><creatorcontrib>Schlüter, Torsten ; Steinbach, Antje C. ; Steffen, Anja ; Rettig, Rainer ; Grisk, Olaf</creatorcontrib><description>Aims The present study was designed to test the hypothesis that NADPH oxidase inhibition with apocynin would lower blood pressure and improve endothelial function in spontaneously hypertensive rats (SHRs). Although apocyin effectively dilated arterial segments in vitro, it failed to lower blood pressure or improve endothelial function. Further experiments were performed in normotensive rats and in NADPH oxidase subunit knock-out mice to test if apocynin-induced vasodilation depends on NADPH oxidase inhibition at all. Methods and results SHRs were treated with apocynin orally or i.v. Arterial pressure was recorded directly. Rat and mouse arterial function was investigated in vitro by small vessel wire myography. NADPH oxidase activity was measured in human granulocytes and in rat vascular preparations. Rho kinase activity was determined by Western blot analysis. Apocynin did not reduce arterial pressure acutely in SHR when given at 50, 100, or 150 mg kg−1 day−1 orally over 1-week intervals or when given i.v. Apocynin potently inhibited granulocyte NADPH oxidase but not vascular NADPH-oxidase-dependent oxygen radical formation unless exogenous peroxidase was added to vascular preparations. Apocynin dilated rat intrarenal and coronary arteries independently of pharmacological interventions that reduce vascular superoxide radical abundance and actions. Aortic rings from p47phox−/− mice were more sensitive to apocynin-induced dilation than wild-type aortic rings. Rho kinase inhibition reduced or prevented the inhibitory effect of apocynin on agonist-induced vasoconstriction and apocynin inhibited the phosphorylation of Rho kinase substrates. Conclusion Apocynin per se does not inhibit vascular NADPH-oxidase-dependent superoxide formation. Its in vitro vasodilator actions are not due to NADPH oxidase inhibition but may be explained at least in part by inhibition of Rho kinase activity. The discrepancy between apocynin-induced vasodilation in vitro and the failure of apocynin to lower arterial pressure in SHR suggests opposing effects on arterial pressure-regulating systems in vivo. Its use as a pharmacological tool to investigate vascular NADPH oxidase should be discontinued.</description><identifier>ISSN: 0008-6363</identifier><identifier>EISSN: 1755-3245</identifier><identifier>DOI: 10.1093/cvr/cvn185</identifier><identifier>PMID: 18596059</identifier><identifier>CODEN: CVREAU</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Acetophenones - pharmacology ; Age Factors ; Animals ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Pressure - drug effects ; Cardiology. Vascular system ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - enzymology ; Endothelium, Vascular - physiopathology ; Female ; Granulocytes - drug effects ; Granulocytes - enzymology ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - enzymology ; Hypertension - physiopathology ; Inbred strains ; Male ; Medical sciences ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; NADPH oxidase ; NADPH Oxidase 2 ; NADPH Oxidases - antagonists &amp; inhibitors ; NADPH Oxidases - genetics ; NADPH Oxidases - metabolism ; Protein Kinase Inhibitors - pharmacology ; Rats ; Rats, Inbred F344 ; Rats, Inbred SHR ; Rho kinase ; rho-Associated Kinases - antagonists &amp; inhibitors ; rho-Associated Kinases - metabolism ; rhoA GTP-Binding Protein - metabolism ; Signal Transduction - drug effects ; Vascular function ; Vasodilation - drug effects ; Vasodilator Agents - pharmacology</subject><ispartof>Cardiovascular research, 2008-11, Vol.80 (2), p.271-279</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03</citedby><cites>FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20775370$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18596059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schlüter, Torsten</creatorcontrib><creatorcontrib>Steinbach, Antje C.</creatorcontrib><creatorcontrib>Steffen, Anja</creatorcontrib><creatorcontrib>Rettig, Rainer</creatorcontrib><creatorcontrib>Grisk, Olaf</creatorcontrib><title>Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition</title><title>Cardiovascular research</title><addtitle>Cardiovasc Res</addtitle><description>Aims The present study was designed to test the hypothesis that NADPH oxidase inhibition with apocynin would lower blood pressure and improve endothelial function in spontaneously hypertensive rats (SHRs). Although apocyin effectively dilated arterial segments in vitro, it failed to lower blood pressure or improve endothelial function. Further experiments were performed in normotensive rats and in NADPH oxidase subunit knock-out mice to test if apocynin-induced vasodilation depends on NADPH oxidase inhibition at all. Methods and results SHRs were treated with apocynin orally or i.v. Arterial pressure was recorded directly. Rat and mouse arterial function was investigated in vitro by small vessel wire myography. NADPH oxidase activity was measured in human granulocytes and in rat vascular preparations. Rho kinase activity was determined by Western blot analysis. Apocynin did not reduce arterial pressure acutely in SHR when given at 50, 100, or 150 mg kg−1 day−1 orally over 1-week intervals or when given i.v. Apocynin potently inhibited granulocyte NADPH oxidase but not vascular NADPH-oxidase-dependent oxygen radical formation unless exogenous peroxidase was added to vascular preparations. Apocynin dilated rat intrarenal and coronary arteries independently of pharmacological interventions that reduce vascular superoxide radical abundance and actions. Aortic rings from p47phox−/− mice were more sensitive to apocynin-induced dilation than wild-type aortic rings. Rho kinase inhibition reduced or prevented the inhibitory effect of apocynin on agonist-induced vasoconstriction and apocynin inhibited the phosphorylation of Rho kinase substrates. Conclusion Apocynin per se does not inhibit vascular NADPH-oxidase-dependent superoxide formation. Its in vitro vasodilator actions are not due to NADPH oxidase inhibition but may be explained at least in part by inhibition of Rho kinase activity. The discrepancy between apocynin-induced vasodilation in vitro and the failure of apocynin to lower arterial pressure in SHR suggests opposing effects on arterial pressure-regulating systems in vivo. Its use as a pharmacological tool to investigate vascular NADPH oxidase should be discontinued.</description><subject>Acetophenones - pharmacology</subject><subject>Age Factors</subject><subject>Animals</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiology. Vascular system</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - enzymology</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Granulocytes - drug effects</subject><subject>Granulocytes - enzymology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - enzymology</subject><subject>Hypertension - physiopathology</subject><subject>Inbred strains</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>NADPH oxidase</subject><subject>NADPH Oxidase 2</subject><subject>NADPH Oxidases - antagonists &amp; inhibitors</subject><subject>NADPH Oxidases - genetics</subject><subject>NADPH Oxidases - metabolism</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Rats</subject><subject>Rats, Inbred F344</subject><subject>Rats, Inbred SHR</subject><subject>Rho kinase</subject><subject>rho-Associated Kinases - antagonists &amp; inhibitors</subject><subject>rho-Associated Kinases - metabolism</subject><subject>rhoA GTP-Binding Protein - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Vascular function</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0008-6363</issn><issn>1755-3245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp90EFLIzEUB_AginbVix9A5qIHYfSlmSSTY6m6XSy6rgoiSMhkEoxOkzqZKfrtN7stihcP4ZG8Hy-8P0J7GI4xCHKiF206Hpd0DQ0wpzQnw4KuowEAlDkjjGyhHzE-pyulvNhEW4kKBlQM0ONoHvS7dz53vu61qbOFiqF2jepc8Jnzi9AsTMz-PIXsxXkVTXp7cpX73676LvOhyy5Hp78nWXhz9VewgzasaqLZXdVtdHd-djue5NOrn7_Go2muCyy63CpWMoIJB1sQY2sKxhLFSEW4AVsBFoITMMCJsFDBUBBWFaqmKq3DsQayjQ6Xc-dteO1N7OTMRW2aRnkT-iiZYKwsWJng0RLqNsTYGivnrZup9l1ikP_ClClMuQwz4f3V1L6amfqTrtJL4GAFVNSqsa3y2sUPNwTOaVrq04V-_v2H-dK52Jm3D6naF8k44VRO7h_kLdzT6c21kBfkL8LMmgA</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Schlüter, Torsten</creator><creator>Steinbach, Antje C.</creator><creator>Steffen, Anja</creator><creator>Rettig, Rainer</creator><creator>Grisk, Olaf</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081101</creationdate><title>Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition</title><author>Schlüter, Torsten ; Steinbach, Antje C. ; Steffen, Anja ; Rettig, Rainer ; Grisk, Olaf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acetophenones - pharmacology</topic><topic>Age Factors</topic><topic>Animals</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiology. Vascular system</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - enzymology</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Granulocytes - drug effects</topic><topic>Granulocytes - enzymology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - enzymology</topic><topic>Hypertension - physiopathology</topic><topic>Inbred strains</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>NADPH oxidase</topic><topic>NADPH Oxidase 2</topic><topic>NADPH Oxidases - antagonists &amp; inhibitors</topic><topic>NADPH Oxidases - genetics</topic><topic>NADPH Oxidases - metabolism</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Rats</topic><topic>Rats, Inbred F344</topic><topic>Rats, Inbred SHR</topic><topic>Rho kinase</topic><topic>rho-Associated Kinases - antagonists &amp; inhibitors</topic><topic>rho-Associated Kinases - metabolism</topic><topic>rhoA GTP-Binding Protein - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Vascular function</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schlüter, Torsten</creatorcontrib><creatorcontrib>Steinbach, Antje C.</creatorcontrib><creatorcontrib>Steffen, Anja</creatorcontrib><creatorcontrib>Rettig, Rainer</creatorcontrib><creatorcontrib>Grisk, Olaf</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schlüter, Torsten</au><au>Steinbach, Antje C.</au><au>Steffen, Anja</au><au>Rettig, Rainer</au><au>Grisk, Olaf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition</atitle><jtitle>Cardiovascular research</jtitle><addtitle>Cardiovasc Res</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>80</volume><issue>2</issue><spage>271</spage><epage>279</epage><pages>271-279</pages><issn>0008-6363</issn><eissn>1755-3245</eissn><coden>CVREAU</coden><abstract>Aims The present study was designed to test the hypothesis that NADPH oxidase inhibition with apocynin would lower blood pressure and improve endothelial function in spontaneously hypertensive rats (SHRs). Although apocyin effectively dilated arterial segments in vitro, it failed to lower blood pressure or improve endothelial function. Further experiments were performed in normotensive rats and in NADPH oxidase subunit knock-out mice to test if apocynin-induced vasodilation depends on NADPH oxidase inhibition at all. Methods and results SHRs were treated with apocynin orally or i.v. Arterial pressure was recorded directly. Rat and mouse arterial function was investigated in vitro by small vessel wire myography. NADPH oxidase activity was measured in human granulocytes and in rat vascular preparations. Rho kinase activity was determined by Western blot analysis. Apocynin did not reduce arterial pressure acutely in SHR when given at 50, 100, or 150 mg kg−1 day−1 orally over 1-week intervals or when given i.v. Apocynin potently inhibited granulocyte NADPH oxidase but not vascular NADPH-oxidase-dependent oxygen radical formation unless exogenous peroxidase was added to vascular preparations. Apocynin dilated rat intrarenal and coronary arteries independently of pharmacological interventions that reduce vascular superoxide radical abundance and actions. Aortic rings from p47phox−/− mice were more sensitive to apocynin-induced dilation than wild-type aortic rings. Rho kinase inhibition reduced or prevented the inhibitory effect of apocynin on agonist-induced vasoconstriction and apocynin inhibited the phosphorylation of Rho kinase substrates. Conclusion Apocynin per se does not inhibit vascular NADPH-oxidase-dependent superoxide formation. Its in vitro vasodilator actions are not due to NADPH oxidase inhibition but may be explained at least in part by inhibition of Rho kinase activity. The discrepancy between apocynin-induced vasodilation in vitro and the failure of apocynin to lower arterial pressure in SHR suggests opposing effects on arterial pressure-regulating systems in vivo. Its use as a pharmacological tool to investigate vascular NADPH oxidase should be discontinued.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18596059</pmid><doi>10.1093/cvr/cvn185</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-6363
ispartof Cardiovascular research, 2008-11, Vol.80 (2), p.271-279
issn 0008-6363
1755-3245
language eng
recordid cdi_proquest_miscellaneous_69668468
source Oxford Journals Online
subjects Acetophenones - pharmacology
Age Factors
Animals
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood Pressure - drug effects
Cardiology. Vascular system
Disease Models, Animal
Dose-Response Relationship, Drug
Endothelium, Vascular - drug effects
Endothelium, Vascular - enzymology
Endothelium, Vascular - physiopathology
Female
Granulocytes - drug effects
Granulocytes - enzymology
Humans
Hypertension
Hypertension - drug therapy
Hypertension - enzymology
Hypertension - physiopathology
Inbred strains
Male
Medical sciences
Membrane Glycoproteins - genetics
Membrane Glycoproteins - metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout
NADPH oxidase
NADPH Oxidase 2
NADPH Oxidases - antagonists & inhibitors
NADPH Oxidases - genetics
NADPH Oxidases - metabolism
Protein Kinase Inhibitors - pharmacology
Rats
Rats, Inbred F344
Rats, Inbred SHR
Rho kinase
rho-Associated Kinases - antagonists & inhibitors
rho-Associated Kinases - metabolism
rhoA GTP-Binding Protein - metabolism
Signal Transduction - drug effects
Vascular function
Vasodilation - drug effects
Vasodilator Agents - pharmacology
title Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apocynin-induced%20vasodilation%20involves%20Rho%20kinase%20inhibition%20but%20not%20NADPH%20oxidase%20inhibition&rft.jtitle=Cardiovascular%20research&rft.au=Schl%C3%BCter,%20Torsten&rft.date=2008-11-01&rft.volume=80&rft.issue=2&rft.spage=271&rft.epage=279&rft.pages=271-279&rft.issn=0008-6363&rft.eissn=1755-3245&rft.coden=CVREAU&rft_id=info:doi/10.1093/cvr/cvn185&rft_dat=%3Cproquest_cross%3E69668468%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c419t-fa68631370f43efd50ef3a63b37e0fb0199730e0739f0b02936b4ad5a55771c03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69668468&rft_id=info:pmid/18596059&rft_oup_id=10.1093/cvr/cvn185&rfr_iscdi=true